Diary - News All news Alizé Pharma 3 : data from its AZP-3404 program in syndromes of severe insulin resistance

Alizé Pharma 3 : data from its AZP-3404 program in syndromes of severe insulin resistance

AZP-3404, an optimized peptide derived from IGFBP-2, improves glucose control in a preclinical model of severe insulin resistance through a new and unique mechanism of action

Lyon, France, March 21, 2019 - Alizé Pharma 3, a transatlantic company specialized in developing therapeutic peptides for the treatment of rare endocrine and metabolic diseases, today announces it will present preclinical results from its AZP-3404 program in syndromes of severe insulin resistance during the Annual Meeting of the Endocrine Society in New Orleans on March 23-26, 2019.

Alizé Pharma 3 : data from its AZP-3404 program in syndromes of severe insulin resistance

AZP-3404, an optimized peptide derived from IGFBP-2, improves glucose control in a preclinical model of severe insulin resistance through a new and unique mechanism of action

Read the press release

Headlines

Our members

ADVANCED BIODESIGN, LAUREAT DU CONCOURS D’INNOVADVANCED BIODESIGN, WINNER OF THE I-NOV INNOVATION COMPETITION (WAVE 7)

The world’s first model of immunized human skin produced by 3D bioprinting

Novadiscovery Continues Global Expansion with the Launch of its US Headquarters in Boston, MA

Contact